Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Conditions
Interventions
SOC + BSB-1001 Dose Escalation Cohort
SOC+BSB-1001 Expansion Dose
Locations
6
United States
City of Hope National Medical Center
Duarte, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Michigan
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Washington University at St Louis
St Louis, Missouri, United States
The Ohio State University
Columbus, Ohio, United States
Start Date
February 4, 2025
Primary Completion Date
February 1, 2029
Completion Date
March 1, 2029
Last Updated
September 18, 2025
NCT03050268
NCT06656494
NCT06465953
NCT07081087
NCT03520647
NCT06859424
Lead Sponsor
BlueSphere Bio, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions